Metronidazol Panpharma

Metronidazole, the active ingredient in Metronidazol Panpharma, is a nitroimidazole antibiotic presented as an injectable solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal diseases in adults and children as prescribed by a healthcare professional.

GNH USA supplies Metronidazol Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Metronidazol Panpharma is a nitroimidazole antibiotic used to manage infections caused by anaerobic bacteria and susceptible protozoa. - Bacterial vaginosis: eradicates the anaerobic bacteria responsible for the condition, relieving discharge and odor. - Trichomoniasis: eliminates Trichomonas vaginalis, curing infection and preventing recurrence. - Amebic dysentery: destroys Entamoeba histolytica trophozoites, reducing intestinal inflammation and diarrhea. - Anaerobic bacterial infections: targets a broad range of anaerobes in intra‑abdominal, pelvic and skin‑soft tissue infections. - Clostridioides difficile infection: suppresses toxin‑producing C. difficile, aiding clinical resolution of severe colitis.

Metronidazol Panpharma may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild headache during treatment. - Diarrhea: loose stools that resolve after therapy.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate medical attention. - Severe allergic reaction (anaphylaxis): rapid onset of hives, swelling, and breathing difficulty. - Peripheral neuropathy: tingling or numbness in extremities, potentially persistent.

Metronidazol Panpharma requires careful clinical consideration before and during therapy. - Assess renal function: adjust use in patients with severe impairment. - Avoid alcohol: risk of disulfiram‑like reaction with flushing and tachycardia. - Monitor for neurotoxicity: report numbness, tingling, or gait disturbances. - Use with caution in pregnancy: category B, benefits must outweigh potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metronidazol Panpharma can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: can increase metronidazole plasma concentrations. - Phenytoin: may reduce metronidazole effectiveness.